J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rippley, R. K.
Right arrow Articles by Wagner, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rippley, R. K.
Right arrow Articles by Wagner, J. A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PHARMACOKINETICS

Human Pharmacokinetics and Interconversion of Enantiomers of MK-0767, a Dual PPAR{alpha}/{gamma} Agonist

Ronda K. Rippley, PhD, Kerri X. Yan, MS, Natalie D. Matthews, RN, BSN, Howard E. Greenberg, MD, Gary A. Herman, MD and John A. Wagner, MD, PhD

From the Department of Drug Metabolism, Merck Research Laboratories, West Point, Pennsylvania (Dr Rippley, Ms Yan); the Department of Clinical Pharmacology, Merck Research Laboratories, Rahway, New Jersey (Ms Matthews, Dr Herman, Dr Wagner); and Thomas Jefferson University, Clinical Research Unit, Department of Pharmacology and Experimental Therapeutics, Philadelphia, Pennsylvania (Dr Greenberg).

MK-0767, a dual peroxisome proliferator-activated receptor (PPAR) {alpha}/{gamma} agonist, has been studied as a potential treatment of type 2 diabetes and dyslipidemia. The pharmacokinetics and interconversion of (+)-(R)-MK-0767 and (-)-(S)-MK-0767 were evaluated following oral administration of each single enantiomer and the racemate to healthy subjects. The results demonstrate that, consistent with in vitro experiments, chiral inversion occurs rapidly in vivo, and interconversion equilibrium favors (+)-(R). After all treatments, a stable ratio (R/S) of 2 to 2.5 was achieved within 8 hours in most individuals, congruent with model-based estimates of interconversion half-life. In addition, the pharmacokinetics of each enantiomer were generally similar regardless of treatment. Modeling and simulation of enantiomer disposition suggest that the observed predominance of (+)-(R)-MK-0767 in plasma may result from differential volumes of distribution between (-)-(S) and (+)-(R), preferential conversion from (-)-(S) to (+)-(R), or a combination of these, but not faster clearance of (-)-(S) compared to (+)-(R).

Key Words: clinical pharmacokinetics • enantiomer • chirality • interconversion • diabetes • mathematical model • simulations • KRP-297

Address for reprints: Address for correspondence: Ronda K. Rippley, PhD, Clinical Drug Metabolism, WP75B-100, PO Box 4, Merck Research Laboratories, West Point, PA 19486-0004; e-mail: ronda_rippley{at}merck.com.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Clinical Pharmacology